Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 887 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ESTRING Clear all
Completed Phase 2 Interventional Results available

Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

NCT00534417
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
capecitabine, fulvestrant
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
Miami, Florida • Athens, Georgia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hormonal Birth Control and the Risk of Acquiring HIV

NCT00006324
View directory record Official record
Conditions
HIV Infections
Interventions
Ethinyl estradiol/levonorgestrel, Medroxyprogesterone acetate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
16 Years to 35 Years · Female only
Enrollment
6,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Desogestrel-containing COCP Pharmacokinetic Validation Study

NCT05002738
View directory record Official record
Conditions
Contraception
Interventions
Desogestrel and Ethinyl Estradiol Tablets
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

The Influence of Testosterone on Experimental Pain Perception

NCT05781685
View directory record Official record
Conditions
Acute Pain
Interventions
Testosterone, Placebo Syrup
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

NCT02116803
View directory record Official record
Conditions
Solid Tumors
Interventions
dovitinib, fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Las Vegas, Nevada • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 2Phase 3 Interventional

Estrogen, HDL, and Coronary Heart Disease in Women

NCT00083824
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Disease, Heart Diseases, Coronary Arteriosclerosis
Interventions
Estrogens, Conjugated (USP), Medroxyprogesterone 17-Acetate, Placebo
Drug
Lead sponsor
Tufts University
Other
Eligibility
55 Years to 80 Years · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 25, 2026, 9:12 PM EDT
Terminated Phase 1 Interventional

Phase I Study of the Combination of MLN9708 and Fulvestrant

NCT02384746
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, MLN9708
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

NCT03363893
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
CT7001, Fulvestrant
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
12
States / cities
Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 4 Interventional Results available

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

NCT03720847
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 25, 2026, 9:12 PM EDT
Terminated Phase 1 Interventional

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

NCT03134638
View directory record Official record
Conditions
Advanced Solid Tumors, Ovarian Cancer, Breast Cancer
Interventions
SY-1365 (Part 1), Carboplatin, Fulvestrant, SY-1365 (Cohort 2), SY-1365 (Cohort 5), SY-1365 (Part 2 Single Agent)
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Not applicable Interventional Results available

Study of SyntheCelTM Dura Replacement to Other Dura Replacements

NCT00859508
View directory record Official record
Conditions
Cranial Dura Repair
Interventions
SyntheCel, Other FDA cleared dura replacements
Device
Lead sponsor
Synthes USA HQ, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Scottsdale, Arizona • Stanford, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

NCT03691493
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Palbociclib, Radiation Therapy, Tamoxifen
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Atlanta, Georgia • Augusta, Georgia • Columbus, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor

NCT01778985
View directory record Official record
Conditions
Pelvic Organ Prolapse, Menopause
Interventions
Premarin, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 25, 2026, 9:12 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

NCT00722800
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
drospirenone and ethinyl estradiol (YAZ), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 25, 2026, 9:12 PM EDT
Terminated Phase 2 Interventional Results available

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

NCT01528345
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dovitinib, Fulvestrant, Dovitinib Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sex Hormones and Orthostatic Tolerance

NCT01153581
View directory record Official record
Conditions
Orthostatic Intolerance
Interventions
Ganirelix acetate, 17β-Oestradiol, Progesterone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 25, 2026, 9:12 PM EDT
Completed No phase listed Observational

Suturable DuraGen™ PMCF Study

NCT04923867
View directory record Official record
Conditions
Cerebrospinal Fluid Leak
Interventions
Suturable DuraGen™
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Aurora, Colorado • Jacksonville, Florida • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 25, 2026, 9:12 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00592007
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
Fulvestrant and Erlotinib
Drug
Lead sponsor
Lyudmila Bazhenova, M.D.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Results available

Endocrine Response in Women With Invasive Lobular Breast Cancer

NCT02206984
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen, Anastrozole, Fulvestrant
Drug
Lead sponsor
Priscilla McAuliffe
Other
Eligibility
Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide, Giredestrant, Tamoxifen
Drug · Combination Product · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration

NCT00589134
View directory record Official record
Conditions
Exercise Induced Hyponatremia
Interventions
Gatorade Endurance Formula, ganirelix acetate
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

Duragen Versus Duraguard in Chiari Surgery

NCT00741858
View directory record Official record
Conditions
Chiari Malformation
Interventions
Duragen duraplasty, Duraguard duraplasty
Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hormonal Contraception and Vaginal Health

NCT00612508
View directory record Official record
Conditions
Contraceptive Usage, Vaginal Epithelial Disruption
Interventions
Desogen (ethinyl estradiol and desogestrel), NuvaRing (ethinyl estradiol and etonogestrel)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Oct 25, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Bleeding With Extended Administration of an Oral Contraceptive

NCT00338052
View directory record Official record
Conditions
Contraception
Interventions
Norethindrone 1 mg / ethinyl estradiol 20 mcg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
25 Years to 40 Years · Female only
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Carmichael, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 8, 2008 · Synced Oct 25, 2026, 9:12 PM EDT